Compare Amgen, Inc. (AMGN) vs First Trust Cloud Computing ETF (SKYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs First Trust Cloud Computing ETF — how do they compare? Amgen, Inc. trades at $356.92 (market cap $196.12B), while First Trust Cloud Computing ETF trades at $140.57. The key difference: Amgen, Inc. pays a 2.77% dividend while First Trust Cloud Computing ETF pays none. Which is the better fit depends on your goals.
| AMGN | SKYY | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | — |
52-Week High | $388.16 | $155.17 |
52-Week Low | $271.18 | $104.16 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
SKYY (First Trust Cloud Computing ETF) trades at $139.77, down 1.47% today, with strong technical momentum indicated by bullish moving averages. The ETF provides diversified exposure to cloud computing companies amid growing enterprise AI adoption. Recent news highlights continued institutional interest in technology ETFs and cloud computing sector strength.
The outlook remains positive as cloud computing benefits from enterprise digital transformation and AI spending acceleration. Key risks include sector concentration and technology volatility. Analyst coverage suggests the ETF offers strategic exposure to a high-growth technology segment with institutional-grade market positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →
